What did a panel of cancer experts rule concerning the cancer drug Avastin? [ori

游客2023-12-11  20

问题 What did a panel of cancer experts rule concerning the cancer drug Avastin?
A panel of cancer experts ruled Wednesday that Avastin—the world’s best-selling cancer drug, developed by Genentech in South San Francisco—should no longer be used in breast cancer patients because of concerns that the medicine didn’t work as well in follow-up studies and may cause deadly bleeding.
    Outside advisers to the Food and Drug Administration voted 6-0 against Avastin’s use in breast cancer at a hearing. Their recommendations will be sent to FDA Commissioner Margaret Hamburg, who will make the final ruling on. Avastin will remain on the market because it’s approved for four other types of tumors—lung, kidney, colon and brain cancer. Approval for those uses won’t be affected by Wednesday’s recommendation.
    The FDA gave Avastin accelerated approval for breast cancer in February 2008 on the basis of one study that suggested the medicine, combined with chemotherapy, slowed tumor growth by 5 1/2 months. Required follow-up tests found Avastin kept cancer at bay for one to two months. (8) The drug was also tied to more life-threatening side effects such as severe bleeding, stomach tears and high blood pressure.
                                                         San Francisco Chronicle

选项 A、It should no longer be used for breast cancer patients.
B、It should no longer be used for all cancer patients.
C、FDA should accelerate the approval for Avastin.
D、More follow-up studies should be made on this drug.

答案 A

解析 主旨题。根据原文,专家小组在这次听证会的投票决议是,Avastin不应该继续用于治疗乳腺癌病人:…Avastin should no longer be used in breast cancer patients…但仍可在市场上销售用于治疗肺癌、肾脏癌、结肠癌和脑部肿瘤等四类肿瘤:Avastin will remain on the market because it’s approved for four other types of tumors--lung,kidney, colon and brain cancer。因此答案选A。
转载请注明原文地址:https://tihaiku.com/zcyy/3264900.html
最新回复(0)